Cited by 28Lysosomal Storage Disorders ResearchParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Prion-like α-synuclein pathology in the brain of infants with Krabbe disease

Open access
Hatton, Christopher, Ghanem, Simona S., Koss, David J., Abdi, Ilham Y., Gibbons, Elizabeth, Guerreiro, Rita, Bras, Jose, International DLB Genetics Consortium +74 more·2022·Brain

Abstract

Krabbe disease is an infantile neurodegenerative disorder resulting from pathogenic variants in the GALC gene that causes accumulation of the toxic sphingolipid psychosine. GALC variants are also associated with Lewy body diseases, an umbrella term for age-associated neurodegenerative diseases in which the protein α-synuclein aggregates into Lewy bodies. To explore whether α-synuclein in Krabbe disease has pathological similarities to that in Lewy body disease, we performed an observational post-mortem study of Krabbe disease brain tissue (n = 4) compared to infant controls (n = 4) and identified widespread accumulations of α-synuclein. To determine whether α-synuclein in Krabbe disease brain displayed disease-associated pathogenic properties we evaluated its seeding capacity using the real-time quaking-induced conversion assay in two cases for which frozen tissue was available and strikingly identified aggregation into fibrils similar to those observed in Lewy body disease, confirming the prion-like capacity of Krabbe disease-derived α-synuclein. These observations constitute the first report of prion-like α-synuclein in the brain tissue of infants and challenge the putative view that α-synuclein pathology is merely an age-associated phenomenon, instead suggesting it results from alterations to biological pathways, such as sphingolipid metabolism. Our findings have important implications for understanding the mechanisms underlying Lewy body formation in Lewy body disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awac002

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many LSDs can feature neurodevelopmental symptoms, such as autism and intellectual disability.

    “Many LSDs can feature neurodevelopmental symptoms, such as autism and intellectual disability.67–69”

    From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [69]

    The Materials and methods table (page not available) records developmental delay in three infants with Krabbe disease, supporting a neurodevelopmental symptom in one lysosomal storage disease. The paper does not establish that many such diseases feature these symptoms, or report autism or intellectual disability. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. [1]Graziano AC, Cardile V. History, genetic, and recent advances on Krabbe disease. Gene. 2015; 555(1): 2– 13. 25260228
  2. [2]Outeiro TF, Koss DJ, Erskine D, et al Dementia with Lewy bodies: An update and outlook. Mol Neurodegener. 2019; 14(1): 5. 30665447 PMC6341685
  3. [3]Chang D, Nalls MA, Hallgrimsdottir IB, et al A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. 2017; 49(10): 1511– 1516. 28892059 PMC5812477
  4. [4]Abdelkarim H, Marshall MS, Scesa G, et al α-Synuclein interacts directly but reversibly with psychosine: Implications for α-synucleinopathies. Sci Rep. 2018; 8(1): 12462. 30127535 PMC6102231
  5. [5]Marshall MS, Issa Y, Heller G, Nguyen D, Bongarzone ER. AAV-Mediated GALC gene therapy rescues alpha-synucleinopathy in the spinal cord of a leukodystrophic lysosomal storage disease mouse model. Front Cell Neurosci. 2020; 14: 619712. 33424556 PMC7785790
  6. [6]Smith BR, Santos MB, Marshall MS, et al Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol. 2014; 232(5): 509– 521. 24415155 PMC3977150
  7. [7]Erskine D, Koss D, Korolchuk VI, et al Lipids, lysosomes and mitochondria: Insights into Lewy body formation from rare monogenic disorders. Acta Neuropathol. 2021; 141(4): 511– 526. 33515275 PMC7952289
  8. [8]Erskine D, Attems J. Insights into Lewy body disease from rare neurometabolic disorders. J Neural Transm (Vienna) 2021; 128(10): 1567– 1575. 34056672 PMC8528771
  9. [9]Poggiolini I, Erskine D, Vaikath NN, et al RT-QuIC using C-terminally truncated α-synuclein forms detects differences in seeding propensity of different brain regions from synucleinopathies. Biomolecules. 2021; 11(6): 820. 34072869 PMC8226794
  10. [10]Han JY, Jang HS, Green AJE, Choi YP. RT-QuIC-based detection of alpha-synuclein seeding activity in brains of dementia with Lewy body patients and of a transgenic mouse model of synucleinopathy. Prion. 2020; 14(1): 88– 94. 32041499 PMC7039666
  11. [11]Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol Dis. 2020; 146: 105086. 32971232
  12. [12]Vaikath NN, Majbour NK, Paleologou KE, et al Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Neurobiol Dis. 2015; 79: 81– 99. 25937088
  13. [13]Raghavan R, Kruijff L, Sterrenburg MD, Rogers Beverly B., Hladik Christa L., White Charles L. Alpha-synuclein expression in the developing human brain. Pediatr Dev Pathol. 2004; 7(5): 506– 516. 15547775
  14. [14]Orme T, Hernandez D, Ross OA, et al Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathol Commun. 2020; 8(1): 5. 31996268 PMC6990558
  15. [15]Guerreiro R, Ross OA, Kun-Rodrigues C, et al Investigating the genetic architecture of dementia with Lewy bodies: A two-stage genome-wide association study. Lancet Neurol. 2018; 17(1): 64– 74. 29263008 PMC5805394
  16. [16]Edison P, Rowe CC, Rinne JO, et al Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008; 79(12): 1331– 1338. 18653550
  17. [17]Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - Current issues and future directions. J Neurochem. 2019; 150(5): 467– 474. 30892688
  18. [18]Van Den Berge N, Ferreira N, Mikkelsen TW, et al Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats. Brain. 2021; 144(6): 1853– 1868. 33880502 PMC8320301
  19. [19]Marshall MS, Jakubauskas B, Bogue W, et al Analysis of age-related changes in psychosine metabolism in the human brain. PLoS ONE. 2018; 13(2): e0193438. 29481565 PMC5826537
  20. [20]Durcan R, Wiblin L, Lawson RA, et al Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease. Eur J Neurol. 2019; 26(7): 979– 985. 30706593 PMC6563450
  21. [21]Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016; 79(6): 940– 949. 27015771
  22. [22]Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: A clinico-pathological study. Brain. 2010; 133: 1755– 1762. 20371510
  23. [23]Shahmoradian SH, Lewis AJ, Genoud C, et al Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019; 22(7): 1099– 1109. 31235907

Cited by

Sorted by citations

Authors
Hatton, C., Ghanem, S. S., Koss, D. J., Abdi, I. Y., Gibbons, E., Guerreiro, R., Bras, J., International DLB Genetics Consortium, Bras, J., Guerreiro, R., Kun-Rodrigues, C., Singleton, A., Hernandez, D., Ross, O. A., Dickson, D. W., Graff-Radford, N., Ferman, T. J., Petersen, R. C., Boeve, B. F., Heckman, M. G., Trojanowski, J. Q., Van Deerlin, V., Cairns, N. J., Morris, J. C., Stone, D. J., Eicher, J. D., Clark, L., Honig, L. S., Marder, K., Serrano, G. E., Beach, T. G., Galasko, D., Masliah, E., Hardy, J., Darwent, L., Ansorge, O., Parkkinen, L., Morgan, K., Brown, K., Braae, A., Barber, I., Troakes, C., Al-Sarraj, S., Warner, T., Lashley, T., Holton, J., Compta, Y., Revesz, T., Lees, A., Zetterberg, H., Escott-Price, V., Pickering-Brown, S., Mann, D., George-Hyslop, P. S., Rogaeva, E., George-Hyslop, P. S., Clarimon, J., Lleo, A., Morenas-Rodriguez, E., Pastor, P., Diez-Fairen, M., Aquilar, M., Compta, Y., Shepherd, C., Halliday, G. M., Tienari, P. J., Myllykangas, L., Oinas, M., Santana, I., Lesage, S., Zetterberg, H., Londos, E., Lemstra, A., Walker, L., Gelpi, E., Heywood, W., Outeiro, T. F., Attems, J., McFarland, R., Forsyth, R., El-Agnaf, O. M., & Erskine, D.
Affiliations
  • Wellcome Centre for Mitochondrial Research (GB)
  • Hamad bin Khalifa University (QA)
  • Newcastle University (GB)
  • Van Andel Institute (US)
  • Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria
  • University College London (GB)
  • German Center for Neurodegenerative Diseases (DE)
  • Great North Children's Hospital (GB)
  • Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha 34110, Qatar
Corresponding author
Erskine, Daniel
Venue
Brain
Published
2022-01-06
Volume
145
Issue
4
Pages
1257-1263
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4206795044
Cited by
28
References
0
Citations by year
2026: 1 · 2025: 9 · 2024: 11 · 2023: 5 · 2022: 2
FWCI
4.18
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion, cc-by-nc)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • Figshare (submittedVersion, cc-by-nc)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • DZNE Pub (submittedVersion, cc-by-nc)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by-nc)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by-nc)
Funders
  • Alzheimer’s Research UK Northern Network (ARUK-RF2018C-005)
  • Qatar Biomedical Research Institute (SF 2017-007)
  • South Tees Hospitals NHS Foundation Trust
  • Lewy Body Society (LBS/007/2020)
  • Deutsche Forschungsgemeinschaft
  • German Research Foundation (EXC 2067/1- 390729940)
  • NHS
  • NIHR
  • Department of Health
Topics
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Krabbe disease, alpha-synuclein, prion-like aggregation, psychosine, GALC gene, Lewy body disease, infantile neurodegeneration, sphingolipid metabolism
MeSH terms
Synucleinopathies, Brain, Humans, Leukodystrophy, Globoid Cell, Prions, Sphingolipids, Lewy Body Disease, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review